GC Green Cross Wellbeing Begins Researcher-Led Clinical Trial on Pain Relief of Placenta Injection 'Rainek'

[Asia Economy Reporter Lee Gwan-joo] GC Green Cross Wellbeing announced on the 1st that it has received approval from the Ministry of Food and Drug Safety for a researcher-initiated clinical IND (Investigational New Drug application) to verify the pain relief efficacy of the hydrolyzed human placenta product 'Rainek'.

This researcher-initiated clinical trial is led by Professor Kim Doo-hwan of the Department of Rehabilitation Medicine at Chung-Ang University Hospital. The study will evaluate the efficacy and safety of Rainek in 50 patients with 'shoulder impingement syndrome'.

Shoulder impingement syndrome is a condition where inflammation is caused by friction between parts of the shoulder blade and arm bone when raising the arm. Severe symptoms can lead to rotator cuff damage and reduced shoulder motor function, resulting in a decreased quality of life. Although this condition has symptoms similar to frozen shoulder, it requires accurate diagnosis and treatment as the causes and treatments differ.

A GC Green Cross Wellbeing official stated, "With the recent shift towards an aging society, the number of chronic pain patients is rapidly increasing," adding, "This study aims to clinically explore the pain relief efficacy of Rainek."

Rainek is a prescription drug for improving liver function in patients with alcoholic and non-alcoholic steatohepatitis, with cumulative sales reaching 65 million doses. In 2020, animal studies confirmed its effects on reducing ligament inflammation and promoting regeneration.